Mizuho Securities Downgrades Spark Therapeutics (ONCE) to Neutral Following Acquisition
Tweet
Share
E-mail
Get Alerts ONCE Hot Sheet
Price: $110.05 --0%
Rating Summary:
5 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 8
Rating Summary:
5 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 8
Join SI Premium – FREE
Mizuho Securities analyst Difei Yang downgraded Spark Therapeutics (NASDAQ: ONCE) from Buy to Neutral with a price target of $114.50.
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $113.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades Rio Tinto Plc. (RIO:LN) (RIO) to Underweight
- UBS Downgrades Man Group Plc. (EMG:LN) (MNGPY) to Neutral
- BNP Paribas Exane Downgrades Acerinox SA (ACX:SM) (ANIOY) to Underperform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
